PCSK9 inhibitors for statin intolerance?

JAMA - Journal of the American Medical Association

Volumn 315, Issue 15, 2016, Pages 1571-1572

  Waters, David D ^a,b   Hsue, Priscilla Y ^a,b   Bangalore, Sripal ^c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; BLOOD; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MUSCULAR DISEASES;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; EZETIMIBE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MUSCULAR DISEASES;

EID: 84964354331     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.3670     Document Type: Editorial

References (18)

1. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36 (17):1012-1022.
2. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
3. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.
4. Hovingh GK, Gandra SR, McKendrick J, et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis. 2016;245:111-117.
5. US Food and Drug Administration (FDA). FDA: Limit Use of 80mg Simvastatin. FDA website. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm257884.htm. Accessed March 13, 2016.
6. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29 (12):1553-1568.
7. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664-669.
8. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3)(suppl):S58-S71.
9. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587.
10. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
11. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. doi:10.1001/jama.2016.3608.
12. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308(23):2497-2506.
13. Stroes E, Colquhoun D, Sullivan D, et al; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548.
14. Moriarty PM, Thompson PD, Cannon CP, et al; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-769.
15. Waters DD, Hsue PY. PCSK9 inhibition to lower LDL-cholesterol and reduce cardiovascular risk: great expectations. Circ Res. 2015;116(10):1643-1645.
16. Institute for Clinical and Economic Review (ICER). PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks Draft Report. ICER website. http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9-Draft-Report-0908151.pdf. September 8, 2015. Accessed March 22, 2016.
17. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32(20):2525-2532.
18. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133 (11):1073-1080.